Get a Free Consultation
Massive Bio and admera health partnership

Massive Bio and Admera Health Partnership

Massive Bio to Present SYNERGY-AI Trial-in-Progress Poster Presentation at Upcoming AACR 2019 using its AI Clinical Trial Matching Technology, and Announces Strategic Partnership in Precision Oncology with US-Based Admera Health

NEW YORK, April 02, 2019 (GLOBE NEWSWIRE) -- Massive Bio, Inc., a leader in providing simplified and affordable access to clinical trials and precision oncology to cancer patients treated at community-based oncology practices, announced today that its Trials-in-Progress poster titled “SYNERGY-AI: Artificial intelligence based precision oncology clinical trial matching and registry” will be presented by Dr. Selin Kurnaz, a lead investigator, at the American Association of Cancer Research (AACR) Annual Meeting 2019 in Atlanta, GA, USA, during the Phase I-III Trials in Progress session on April 2nd, 2019.

The poster (Abstract #CT218),  discusses the ongoing, pivotal global registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool powered by a virtual tumor board (VTB) program. The SYNERGY-AI registry is the first of its kind to combine artificial intelligence, genomic biomarkers and multi-variate analysis to accelerate clinical trial matching and promote access to promising cancer therapies.

“We continue active enrollment in this innovative precision oncology and artificial intelligence project, and we are honored and excited to be among the highly selected group of clinical trials to be presented at AACR. Moreover, we are the only company in the market that operationalizes technology – we not only pre-screen patients, we find sites to the patients, eliminate insurance barriers and truly close the last mile in oncology clinical trial enrollment. We clean massive operational inefficiencies and we are making a leap frog in clinical research,” said Selin Kurnaz, PhD., CEO and Co-Founder of Massive Bio.

In addition, today, Massive Bio and Admera Health announced a non-exclusive collaborative agreement as active participants in SYNERGY-AI registry. Under the terms of the agreement, Massive Bio and Admera Health will focus on real world evidence, biomarker data and clinical trial matching in precision oncology studies. In addition, Admera Health also provides genomics and bioinformatics services to customers wishing to conduct research in a CLIA environment.

“By combining the expansive technology and precision oncology capabilities of Massive Bio with Admera Health’s specialization in genomics and bioinformatics, we hope to develop and provide the next wave of molecular-based portfolio of technology innovations and services,” stated Jeffrey R. Mitchell, Associate Director of Strategy and Marketing of Admera Health. Mitchell continued, “In addition, given the geographic strengths of our respective companies, there will also be opportunities to expand clinical trials using each other’s proprietary technology around the globe.”

Commenting on the announcement, Chief Medical Advisor and Co-Founder of Massive Bio Inc., Dr. Arturo Loaiza-Bonilla, MD, MSEd, stated, “Massive Bio’s Artificial Intelligence technology platform is extremely well positioned to enable just-in-time clinical trial matching and enrollment, with a targeted therapy and immunotherapy focus, and is proven to accelerate access to innovative therapies, sponsor and CRO efficiency, as well as time to market. We certainly welcome collaborations with all stakeholders in the diagnostics and research space, aiming to close existing gaps in cancer research.” Chief Business Officer of Massive Bio Inc, Harry Buchman also stated, “With a growing number of successful development applications, it is our goal to continue to promote precision oncology approaches at the point-of-care, and to ease access to clinical trials, while reducing patient and provider burden and overall cancer care costs.”

About the Study

The SYNERGY-AI Registry is an international prospective, observational cohort study of adult and pediatric patients with advanced solid and hematological malignancies. Using a proprietary application programming interface (API) linked to existing electronic health records (EHR) platforms, individual clinical data is extracted, analyzed and matched to a parametric database of existing institutional and non-institutional CT. Machine learning algorithms allow for optimized matching based on CT allocation and availability. Enrollment is ongoing, with a target of ≥1,500 patients. Please refer to for details.

About Massive Bio, Inc.

Massive Bio connects patients and their treating oncologist to the best available treatment options including clinical trials while enabling enterprises to get access to patients at community practices to enhance oncology research. Massive Bio provides virtual tumor board, clinical trial services (patient identification, pre-screening, site selection) and real-world evidence services. Massive Bio’s enterprise customers are Contract Research Organizations (CROs), pharmaceutical companies, diagnostics labs and providers. Massive Bio’s clinical trial enrollment rate is 4x greater than national standards because of its AI based algorithms, granular review of inclusion/exclusion criteria, education of patient and oncologist and expert driven customer support.

About Admera Health

Admera Health is a CLIA-certified and CAP-accredited advanced molecular diagnostics company focused on personalized medicine, non-invasive cancer testing, digital health, and providing research use only services. Research and development efforts are dedicated to developing cutting-edge diagnostics that span the continuum of care. Utilizing next-generation technology platforms and advanced bioinformatics, Admera Health seeks to redefine disease screening, diagnosis, treatment, monitoring, and management through its innovative, personalized solutions. It is our mission to deliver transformative, valuable solutions for patients, physicians, and clinical researchers. We are committed to improving the health and well-being of our global community through the direct delivery of personalized medically actionable results.

Massive Bio Contact:

Massive Bio Selin Kurnaz, PhD., 844-627-7246 Co-Founder and CEO

Admera Health Contact: Brady Millican VP of Business Development 908-222-0533

Massive Bio to Present SYNERGY-AI Trial in Progress Poster Presentation at Upcoming AACR 2019

Leave a Reply

Your email address will not be published. Required fields are marked *

Join our community
and receive our newsletter